NCT07157514Phase 2, phase 3Not yet recruiting

Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2029-02Estimated

Enrollment · participants306Estimated

Source updated2025-09-10Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Acute Leukemia; Myeloid Leukemia; Acute Myelogenous Leukemia; Acute Myeloid Leukemia; Acute Myeloid Leukemia, in Relapse; Myelogenous Leukemia; Myelogenous Leukemia, Acute; Myelogenous Leukemia in Relapse; Transplant-Related Disorder; Allogeneic Disease; Refractory AML

Treatments or interventions studied

131I-apamistamabDrug
FludarabineDrug
CyclophosphamideDrug
Allogeneic Hematopoietic Stem Cell Transplant (HSCT)Biological

Primary outcomes · main study measures

Read the study measures

measure: Overall Survival (OS) -Phase 3; description: Defined as time from randomization to death from any cause. Subjects without documented death at the time of analysis will be censored at the date of last known contact.; timeFrame: Up to 5 years post-randomization; measure: Complete Remission (CR) at Day 28 Post-HSCT - Phase 2; description: Number of subjects achieving CR by Day 28 (±3 days) post-HSCT, based on bone marrow assessment.; timeFrame: Day 28 post-HSCT; measure: Incidence of Grade ≥4 Non-Hematologic Toxicity; description: Number and proportion of subjects developing grade ≥4 non-hematologic toxicities as graded by NCI CTCAE v5.0.; timeFrame: Up to 6 months post-HSCT

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history